[vc_row][vc_column][vc_column_text css_animation=”fadeInDown”]
Is ImmunoGen Inc (IMGN) Still A Cheap Healthcare Stock?
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_column_text css_animation=”fadeInLeft”]ImmunoGen Inc (NASDAQ:IMGN), a USD$653.50M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalence of diseases and comorbidities. The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term. Healthcare analysts are forecasting for the entire industry, a somewhat weaker growth of 6.42% in the upcoming year , and a massive growth of 43.65% over the next couple of years. Not surprisingly, this rate is more than double the growth rate of the US stock market as a whole. Is the biotech industry an attractive sector-play right now? Below, I will examine the sector growth prospects, as well as evaluate whether IMGN is lagging or leading its competitors in the industry.[/vc_column_text][/vc_column][vc_column width=”1/2″][vc_raw_html]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[/vc_raw_html][/vc_column][/vc_row][vc_row][vc_column][vc_raw_html]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[/vc_raw_html][vc_column_text css_animation=”fadeIn”]
What’s the catalyst for IMGN’s sector growth?
Data analytics and other technology-enabled approaches are creating opportunities for innovations, however, stakeholders have been challenged to keep abreast of this structural shift while under pressure to cut costs. Over the past year, the industry saw negative growth of -60.80%, underperforming the US market growth of 4.49%. IMGN leads the pack with its impressive earnings growth of 26.88% over the past year. Furthermore, analysts are expecting this trend of above-industry growth to continue, with IMGN poised to deliver a 11.79% growth over the next couple of years. This growth may make IMGN a more expensive stock relative to its peers.
Is IMGN and the sector relatively cheap?
The biotech industry is trading at a PE ratio of 31x, higher than the rest of the US stock market PE of 22x. This illustrates a somewhat overpriced sector compared to the rest of the market. However, the industry did return a higher 15.86% compared to the market’s 9.99%, which may be indicative of past tailwinds. Since IMGN’s earnings doesn’t seem to reflect its true value, its PE ratio isn’t very useful. A loose alternative to gauge IMGN’s value is to assume the stock should be relatively in-line with its industry.
What this means for you:
Are you a shareholder? IMGN’s industry-beating future is a positive for shareholders, indicating they’ve backed a fast-growing horse. If you’re bullish on the stock and well-diversified by industry, you may decide to hold onto IMGN as part of your portfolio. However, if you’re relatively concentrated in biotech, you may want to value IMGN based on its cash flows to determine if it is overpriced based on its current growth outlook.
Are you a potential investor? If IMGN has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry. However, before you make a decision on the stock, I suggest you look at IMGN’s future cash flows in order to assess whether the stock is trading at a reasonable price, as well as other important fundamentals such as the company’s financial health in order to build a holistic investment thesis.
For a deeper dive into ImmunoGen’s stock, take a look at the company’s latest free analysis report to find out more on its financial health and other fundamentals. Interested in other healthcare stocks instead? Use our free playform to see my list of over 1000 other healthcare companies trading on the market.[/vc_column_text][vc_raw_html]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[/vc_raw_html][/vc_column][/vc_row]